Fish Oil and Blood Thinners: What the Evidence Shows
Fish oil is one of the most commonly used supplements — and one of the few that cardiologists and anticoagulation clinics specifically ask patients about. Omega-3 fatty acids have measurable effects on platelet function and bleeding tendency, and those effects overlap with how blood-thinning medications work. Understanding where the evidence is solid and where it is murkier makes this a more tractable question than it first appears.
How omega-3s affect platelet function
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — the two omega-3s in fish oil — influence platelet aggregation through their effects on thromboxane and prostacyclin production. They shift the balance between these two prostaglandins in a direction that reduces platelet clumping. In practical terms, high-dose omega-3s can mildly prolong bleeding time.
This is not a trivial pharmacological effect. Prescription omega-3 formulations are used at 4 g/day for cardiovascular risk reduction, and at those doses bleeding risk is a recognized clinical consideration. Over-the-counter fish oil supplements are typically lower dose, but the effect scales with dose.
The combination with blood thinners
Warfarin works by inhibiting vitamin K-dependent clotting factors, reducing the blood's ability to form clots via the coagulation cascade. Omega-3s act on a different part of the hemostasis system — platelet aggregation — but both reduce the blood's overall clotting tendency. Whether the combination produces a clinically meaningful change in INR (the measure used to monitor warfarin dosing) is genuinely debated: some studies have found small INR increases with fish oil plus warfarin; others have not. The evidence is mixed on the anticoagulant-effect side specifically.
What is less debated is the additive effect on bleeding risk overall: two agents that each reduce clotting tendency through different mechanisms create an additive biological effect, even if one marker (INR) does not change measurably. The NIH ODS omega-3 fact sheet notes this interaction context. Aspirin and clopidogrel raise the same concern — both are antiplatelet drugs, and omega-3s add platelet suppression through a separate pathway on top of what those drugs already do.
People on anticoagulants or antiplatelet therapy who take fish oil supplements should let their prescribing provider or anticoagulation clinic know. The combination is not necessarily unsafe, but it is relevant clinical information for anyone monitoring bleeding risk.
Dose and surgical context
The clinical evidence for a meaningful bleeding interaction comes mainly from studies at higher doses — the 2–4 g EPA+DHA range used in cardiovascular trials. At lower over-the-counter doses (typically 0.5–1 g EPA+DHA per serving), the effect may be smaller, but the combination is still routinely flagged in clinical practice.
A related practical concern: many surgeons ask patients to stop fish oil before elective procedures because the antiplatelet effect can increase surgical bleeding. This reflects the same underlying biology — it is not a drug-drug interaction in the traditional sense, but the reason to mention fish oil use to a surgical team is the same reason to mention it to an anticoagulation clinic.
Source: Omega-3 Fatty Acids — Health Professional Fact Sheet (NIH Office of Dietary Supplements)